Skip to main content
GPCR
NASDAQ Life Sciences

Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$21.41
Mkt Cap
$1.451B
52W Low
$18.7
52W High
$94.9
52W Position info
14% above low
Off High info
77% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

GPCR is trading near its 52-week low of $18.7 (14% above the low).

Summary

Structure Therapeutics reported a Q3 2026 net loss of $144.8M as Phase 3 spending ramped, backed by $1.2B in cash it says funds operations through 2028. Phase 3 aleniglipron topline is not due until 2H 2028, with three supplementary datasets expected in Q4 2026.


Key Events · Earnings and Guidance · GPCR

  • Q3 Net Loss Widens to $144.8M

    Net loss was $144.8M versus $65.7M in Q3 2025, including $12.7M of non-cash share-based compensation.

  • R&D Spend Nearly Doubles

    R&D rose to $134.6M from $59.0M a year earlier on clinical trial, preclinical and employee costs; G&A rose to $21.8M from $14.8M.

  • $1.2B Cash Funds Operations Through 2028

    Cash, cash equivalents and short-term investments totaled $1.2B at September 30, 2026, down from $1.3B at June 30, 2026, funding milestones through end-2028 excluding pre-commercialization costs.

  • Phase 3 Topline Slated for 2H 2028

    ACCOMPLISH-1 (up to 3,600 patients) and ACCOMPLISH-2 (up to 1,100 patients with T2DM) are enrolling; topline data expected in the second half of 2028.


Analysis · GPCR · Life Sciences

Spending is ramping hard as the Phase 3 ACCOMPLISH program for aleniglipron gets underway, and the quarterly numbers reflect it: R&D jumped to $134.6M from $59.0M a year ago, pushing the net loss to $144.8M from $65.7M. The offset is a $1.2B cash pile that management says funds operations and key clinical milestones through the end of 2028, so there is no near-term financing need. For valuation, the pipeline update is the part that matters: Phase 3 topline is not expected until 2H 2028, but three supplementary aleniglipron datasets (body composition, T2DM, SWITCH) are due in Q4 2026 and ACCG-2671 MAD data in 1H 2027 — those readouts are the nearer-term drivers.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GPCR was trading at $21.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.70 to $94.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GPCR - Latest Insights

GPCR
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $21.50 info
Change: +$0.090 (+0.42%) info
Market Cap: $1.527B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $21.50 info
Change: -$15.28 (-42%) info
Market Cap: $1.527B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $21.50 info
Change: -$26.10 (-55%) info
Market Cap: $1.527B info
GPCR
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $47.50
Real-time Price: $21.50 info
Change: -$26.00 (-55%) info
Market Cap: $1.527B info
GPCR
Aug 06, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.62
Real-time Price: $21.50 info
Change: -$31.12 (-59%) info
Market Cap: $1.527B info